Pharmaceutical researchers have developed an orally disintegrating tablet formulation of tegoprazan using a self-emulsifying semi-solid dispersion system that significantly enhances the drug’s solubility and oral bioavailability. The newly designed dosage form achieved rapid disintegration within thirty seconds and generated approximately 1.5-fold higher oral bioavailability in animal pharmacokinetic testing compared to the raw active pharmaceutical ingredient.
To address these physicochemical limitations, the investigative team explored whether a lipid-based semi-solid dispersion could simultaneously sustain robust self-emulsifying characteristics and provide the mechanical resilience necessary for conversion into a solid tablet designed for rapid oral disintegration.
The formulation system was prepared using a fusion method based on Gelucire 44/14 and Labrasol excipients. The investigators systematically optimized the preparation through a full factorial design, varying both the lipid composition and the drug-to-lipid ratio. Following this optimization, the semi-solid mixture was adsorbed onto a solid carrier to yield granules, which were subsequently compressed into finished orally disintegrating tablets.
Comprehensive solid-state characterization was conducted to verify the physical state and distribution of the drug within the carrier matrix. The researchers employed scanning electron microscopy, powder X-ray diffraction, differential scanning calorimetry, and thermogravimetric analysis to evaluate the material properties. These analytical evaluations confirmed that tegoprazan was successfully transformed into an amorphous state within the lipid dispersion system.
Evaluation of the optimized semi-solid dispersion revealed substantial improvements in aqueous solubility along with the spontaneous generation of stable nano-sized emulsion droplets upon hydration.
In vitro release testing showed that the tablet formulation released more than 95 percent of the incorporated drug within 180 minutes. This dissolution profile represented an approximately 1.7-fold enhancement in drug release when evaluated alongside raw tegoprazan powder under equivalent experimental conditions.
In vivo pharmacokinetic evaluations performed in rat models corroborated the in vitro dissolution enhancements. Following oral administration to rats, the optimized tablet formulation produced an area under the plasma concentration-time curve approximately 1.5-fold greater than that obtained with the unmodified raw drug substance, confirming improved systemic exposure.
The study authors concluded that integrating a Gelucire 44/14 and Labrasol self-emulsifying semi-solid dispersion into an orally disintegrating tablet provides an effective, practical, and scalable formulation strategy to overcome the solubility and bioavailability barriers of poorly water-soluble compounds.
Subject of Research: Orally disintegrating tablet formulation of tegoprazan using a self-emulsifying dispersion
Article Title: Orally disintegrating tablet formulation of tegoprazan based on a self-emulsifying semi-solid dispersion
Article References: Yoon, K., Lee, J., Choi, S., Kim, J., Kim, H., Caisse, P., Won, J., Lee, E., Kang, W., & Lee, S. (2026). Orally disintegrating tablet formulation of tegoprazan based on a self-emulsifying semi-solid dispersion. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00837-y
Image Credits: AI Generated
DOI: 10.1007/s40005-026-00837-y
Keywords: tegoprazan, orally disintegrating tablets, self-emulsifying dispersion, Gelucire 44/14, Labrasol, oral bioavailability, drug solubility, pharmacokinetics, rat study, amorphization, dissolution rate, powder X-ray diffraction, differential scanning calorimetry, thermogravimetric analysis, scanning electron microscopy, lipid formulation
News Source: Ophelia Keating. (November 20, 2026). Novel Orally Disintegrating Tablet Boosts Tegoprazan Bioavailability in Rat Study. Scienmag.



